Abstract

EMERGING THERAPY FOR DENGUE

Sajan Kumari*, Mrs. Jyoti Kumari and Rajaram R. and Rajbhar*

ABSTRACT

Dengue fever (DF) is an acute febrile disease caused by one of the four closely related virus serotypes of the genus Flavivirus, family Flaviviridae. Each serotype (DEN-1, DEN-2, DEN-3, and DEN-4) is sufficiently distinct that there is no cross-protection among them, and epidemics involving multiple serotypes may occur simultaneously. The disease is transmitted to humans primarily by the Aedes aegypti mosquito. Anti-dengue therapeutic approaches, such as host modulators, antiviral agents, and RNA interference (RNAi) therapeutics, are being investigated for the treatment of dengue. It is therefore essential to enhance understanding of the disease’s prevalence, changes in viral strains, variations in the severity pattern, and the importance of early virus detection and disease management, which contribute to improved recovery outcomes. Population growth, rapid urbanization, increased international travel from dengue-endemic regions, and global warming play major roles in the transmission and spread of the disease. Furthermore, several new vaccine candidates are under evaluation for their safety and efficacy in preventing dengue infection. This review highlights the nuances in the current standard-of-care treatment for dengue and discusses emerging therapeutic strategies, antiviral drugs, and vaccines currently in various stages of preclinical and clinical development.

Keywords: The disease is transmitted to humans primarily by the Aedes aegypti mosquito.